SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS

Size: px
Start display at page:

Download "SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS"

Transcription

1 SEMINAR ON NONCOMPARTMENTAL PHARMACOKINETICS Presented by: Ch. Karthik Siva Chaitanya M.Pharm (1 st sem),pharmaceutics UCPSc,KU. 1

2 Contents: Introduction to noncompartmental pharmacokinetic approach Differences between compartment and noncompartment models Concepts of noncompartmental model Statistical moments theory-mean residence time Different pharmacokinetic parameters in noncompartment model Sem,UCPSc,KU 2

3 Noncompartment pharmacokinetics is a new approach devised to study the time course of drug in the body with out assuming any compartment model. Based on the statistical moment theory. Model independent method Overcomes some of the drawbacks associated with classical compartment modeling. Basic assumption is that drug or metabolite follows first-order kinetics. Sem,UCPSc,KU 3

4 Noncompartment and Compartment models Comparison Compartment models Noncompartment models These require elaborate assumptions to fit the data Curve fitting of experimental data using computers. It is a tedious method. Applicable to linear and nonlinear pharmacokinetics Do not require assumptions to compartment model. Simple algebraic equations. No curve fitting and no computers Applicable to linear pharmacokinetics. C1 - time profile is regarded as expressions of exponents These are useful for most of the situations, though assumptions of modeling are involved. C1 time profile is regarded as statistical distribution. Particularly useful for the applications of clinical pharmacokinetics, bioavailability, and bioequivalence studies. Sem,UCPSc,KU 4

5 Advantages: Derivation of PK parameters is easy, because of simple algebraic equations Mathematical treatment remains same, for drug or metabolite, provided elimination follows first order kinetics Drug disposition kinetics need not be described in detail Sem,UCPSc,KU 5

6 Disadvantages: Information regarding plasma drug concentrationtime profile is expressed as an average Generally not useful for describing the time course of drug in the blood It is applicable only for linear pharmacokinetics Sem,UCPSc,KU 6

7 Statistical Moment Theory Statistical moment: A mathematical description of a discrete distribution of data. Statistical moments calculated from a set of concentration-time data represent an estimate of the true moment (or the true probability density function (PDF)that describes the true relationship between concentration and time). Statistical moment theory provides a unique way to study time-related changes in macroscopic events. Assume the drug molecules are eliminated according to a kinetic function, f(t) = C 0 e kt Sem,UCPSc,KU 7

8 Eq.1 2 [AUC] 0 = C dt 1 3 [AUMC] 0 = t x C. dt Sem,UCPSc,KU 8

9 I.V. bolus injection Calculation of AUC and AUMC Sem,UCPSc,KU 9

10 Mean residence time(mrt): The term mean residence time (MRT) describes the average time for all the drug molecules to reside in the body. Sem,UCPSc,KU 10

11 MRT represents the time for 63.2% of drug eliminated when given i.v. bolus injection. It is analogous to plasma elimination half life, t1/2, i.e., 50% elimination. Like half life, MRT is a function of both distribution and elimination For i.v bolus dose Sem,UCPSc,KU 11

12 In noncompartmental terms, k is constant equal to ratio of clearance to Vss Vss is volume of distribution at steady state Plasma elimination half life : t 1/2 = t1/2 = 0.693MRT MRTiv is used for comparison. For eg: following constant rate of infusion k 10 Where T = duration of infusion Sem,UCPSc,KU 12

13 DRUG ABSORPTION: MAT(Mean absorption time) is defined as the differences in mean residence time (MRT) after different modesof administration. MAT = MRTni MRTiv MRTni = mean residence time of drug by noninstantaneous route, h MRTiv = mean residence time of drug by i.v. bolus injection Same equation is used for i.m. injection Sem,UCPSc,KU 13

14 When absorption follows zero order T = time over which absorption takes place, h MAT can be used for comparision of dosage forms Sem,UCPSc,KU 14

15 OTHER APPLICATIONS OF MRT Mean Dissolution Time(MDT) MDT=MRTtest-MRTsoln In oral administration, MRToral=MRTiv+1/Ka For evaluation of absorption data, MAT=MRTtest-MRTiv MAT=1/Ka Ka is first order absorption rate constant Sem,UCPSc,KU 15

16 Drug Clearance: After iv bolus administration, At steady state after constant rate iv infusion Ko is rate of infusion ; Css is steady state concentration By using extraction ratio Cl=Q(ER) Sem,UCPSc,KU 16

17 APPARENTVOLUME OF DISTRIBUTION: is volume of distribution at steady state independent of elimination Vss Vss =i.v dose(aumc)/(auc) If drug is given by constant rate i.v infusion Where Ko is infusion rate; is duration of infusion Sem,UCPSc,KU 17

18 Steady State Plasma Drug Concentration: The Css is a function of the effective rateof dosing and total body clearance of thedrug in a patient Sem,UCPSc,KU 18

19 AUCss is AUC from t=0 to t= during a dosinginterval at steady state F is fraction bioavailable Method of superposition is used for predicting steady state concentration on repetitive dosing from data obtained after a single dose. Sem,UCPSc,KU 19

20 Predicting the Time to Steady State: Time required for the drug to reach steady state, i.e., 99%, takes 6.65 half lives. In extravascular route (or prolongedrelease drug products), the time requiredto attain ss takes longer than predicted bybiological half life In multicompartment disposition, timerequired to attain to ss is shorter than that predicted by terminal half life Sem,UCPSc,KU 20

21 In noncompartmentmodels, when the drug isadministered repetitive dosing, fss AUC = area under the curve in single dose Sem,UCPSc,KU 21

22 Bioavailability: Bioavailability refers to the fractional dose of a dosage form reaches systemic circulation. For i.v. bolus injection, bioavailability is referred as unity (=1) Bioavailability (F) of a dosage form Sem,UCPSc,KU 22

23 Fraction metabolised: Fraction metabolized, Fm = AUC x 1 AUC 1 AUC x 1 is area under the curve of metabolite concentrationin plasma versus time from zero to infinity AUC 1 is the total area under the metabolite concentration time curve after a equimolar intravenous dose of a metabolite Sem,UCPSc,KU 23

24 CONCLUSION: The noncompartmental pharmacokinetic methods permit a comprehensive pharmacokinetic analysis with out resort to curve fitting,sophisticated computers or tedious mathematical equations. Although these methods cannot be applied to all pharmacokinetic problems,they are useful for most problems and are particularly useful for the clinical application of pharmacokinetics. Sem,UCPSc,KU 24

25 References: Milo Gibaldi, Biopharmaceutics and clinical pharmacokinetics, 4 th edition,pg no D.Perrier,M.Gibaldi Pharmacokinetics, 2 nd edition, pg no Leon Shargel,Applied biopharmaceutics and pharmacokinetics,5 th edition,pg no V.Venkateshwarlu,Biopharmaceutics and pharmacokinetics, pg no Sem,UCPSc,KU 25

26 THANK YOU Sem,UCPSc,KU 26

PHARMACOKINETICS. Dr. M.Mothilal Assistant professor

PHARMACOKINETICS. Dr. M.Mothilal Assistant professor PHARMACOKINETICS Dr. M.Mothilal Assistant professor 1 OVERVIEW Basic considerations in pharmacokinetics Compartment models One compartment model Assumptions Intravenous bolus administration Intravenous

More information

Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal

Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents

More information

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/016/00-corr-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINES FOR THE CONDUCT

More information

Injectable modified release products

Injectable modified release products Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the

More information

Biomath M263 Clinical Pharmacology

Biomath M263 Clinical Pharmacology Training Program in Translational Science Biomath M263 Clinical Pharmacology Spring 2014 www.ctsi.ucla.edu/education/training/webcasts Wednesdays 3 PM room 17-187 CHS 4/2/2014 Pharmacokinetics (PK) and

More information

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited

Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs. Nikunjkumar Patel, Simcyp Limited Use of Mechanistic Population Based PBPK Models in the Establishment and Application of IVIVCs Nikunjkumar Patel, Simcyp Limited IVIVC and Its Components CONVOLUTION VALIDATION DECONVOLUTION MODELS IVIVC

More information

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética COURSE DATA Data Subject Code 34081 Name Biopharmacy and Pharmacokinetics Cycle Grade ECTS Credits 10.5 Academic year 2014-2015 Study (s) Degree Center Acad. Period year 1201 - Grado de Farmacia FACULTY

More information

Pharmacokinetic & Pharmacodynamic Data Analysis

Pharmacokinetic & Pharmacodynamic Data Analysis Pharmacokinetic & Pharmacodynamic Data Analysis CONCEPTS AND APPLICATIONS 4TH EDITION REVISED AND EXPANDED Table of Contents 1. 1.1 1.2 1.3 1.4 1.5 2. 2.1 2.2 2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 2.2.7

More information

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics Biopharmaceutics Lecture :1 Module Introduction and Introduction to Biopharmaceutics Assist. Lecturer Ali Yaseen Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of

More information

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC

Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC Conventional versus Physiologically-Based (PB)-IVIVC: Revisiting Some Successful and Failed Conventional IVIVC Cases with PB-IVIVC Nikunj Patel, Senior Research Scientist Simcyp (a Certara Company) AAPS

More information

BIOPHARMACEUTICS AND PHARMACOKINETICS

BIOPHARMACEUTICS AND PHARMACOKINETICS BIOPHARMACEUTICS AND PHARMACOKINETICS (JULIO 2015) Degree in PHARMACY University of Alcalá Academic year 2015/16 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code:

More information

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season BIOPHARMACEUTICS AND PHARMACOKINETICS Degree in PHARMACY University of Alcalá Academic year 2016/17 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code: 570014 Degree:

More information

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY

II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week THEORY II Semester M.PHARM (PHARMACEUTICS) MPH2A.1: ADVANCED PHYSICAL PHARMACEUTICS 3 Hrs/Week Solubility: Solubility of solid in liquids, Theory of solution formation. Solubilisation techniques using surfactants,

More information

Oral Delivery of Drugs

Oral Delivery of Drugs Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires

More information

Official Letter from the DOH

Official Letter from the DOH Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please

More information

On applications of conservation laws in pharmacokinetics

On applications of conservation laws in pharmacokinetics On applications of conservation laws in pharmacokinetics S.Piekarski (1), M.Rewekant (2) Institute of Fundamental Technological Research Polish Academy of Sciences (1), Medical University of Warsaw, Poland

More information

Bioavailability and Bioequivalence Studies

Bioavailability and Bioequivalence Studies Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98

More information

Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists

Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists

More information

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D BY Mohammed Mahmoud Academic Session 147-8 1 st Semester (Semester No 71)

More information

Dr. M.Mothilal Assistant professor

Dr. M.Mothilal Assistant professor Dr. M.Mothilal Assistant professor Complex picture of drug interactions in the body. This slide gives an idea of the complexity of drug disposition. Shown in this slide are many of the steps to getting

More information

In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation

In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation In silico Prediction of Bioavailability of Pharmaceutical Formulations Using Population Pharmacokinetic Model Simulation Uthpali Mannapperuma Mahidol University Department of Pharmacy, Faculty of Pharmacy,

More information

Making PK Analysis Easier: The New ADaM Data Standard ADNCA

Making PK Analysis Easier: The New ADaM Data Standard ADNCA Paper DS07 Making PK Analysis Easier: The New ADaM Data Standard ADNCA Peter Schaefer, VCA-Plus, Inc., Raleigh, U.S.A. ABSTRACT Noncompartmental analysis ( NCA ) of the pharmacokinetic ( PK ) characteristics

More information

Course Curriculum for Master Degree in Pharmaceutical Technology

Course Curriculum for Master Degree in Pharmaceutical Technology Course Curriculum for Master Degree in Pharmaceutical Technology The Master Degree in Pharmaceutical Technology is awarded by the Faculty of Graduate studies at Jordan University of Science and Technology

More information

Pharmacokinetics in clinical oncology

Pharmacokinetics in clinical oncology Pharmacokinetics in clinical oncology Carlos Ochoa Biostatistics Journal Club Zurich, 27 March 2013 Pharmacokinetics in clinical oncology Anticancer drug effects: Shrink tumour size Slow tumour growth

More information

IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC

IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC IVIVC IMPORTANCE OF IVIVC AND METHODS OF ESTABLISHING IVIVC 1. INTRODUCTION The therapeutic efficacy of pharmaceutical formulations is governed by factors related to both the in vitro dissolution characteristics

More information

Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics

Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics Review 1. Introduction to AMS 2. Background 3. Intravenous pharmacokinetics 4. HPLC AMS 5. FDA guidance on safety testing of drug metabolites 6. Supplementary information 7. Expert opinion Biomedical accelerator

More information

BIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY

BIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY VICH GL 52 (BIOEQUIVALENCE) November 2013 For consultation at Step 4 - Draft 4 BIOEQUIVALENCE: BLOOD LEVEL BIOEQUIVALENCE STUDY Recommended for Consultation at Step 4 of the VICH Process in November 2013

More information

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1 Institute of Pharmaceutical Technology and Biopharmacy University of Pécs 2017. szeptember 22. 1 Pre-discovery Goal: Understand the disease and choose a target molecule. How: Scientists in pharmaceutical

More information

Application of PBPK Models in Assessment of Bioequivalence

Application of PBPK Models in Assessment of Bioequivalence Application of PBPK Models in Assessment of Bioequivalence Robert Lionberger, Ph.D. Acting Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation and Research, FDA

More information

Eurofins ADME BIOANALYSES Your partner in drug development

Eurofins ADME BIOANALYSES Your partner in drug development Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant

More information

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC

Mechanistic IVIVC Using the Simcyp ADAM Model. Make SCIENCE out of IVIVC Mechanistic IVIVC Using the Simcyp ADAM Model Make SCIENCE out of IVIVC %Dissolved in vivo % Dissolved/Absorbed %Dissolved/Absorbed Plasma Conc (ng/ml) IVIVC and Its Components IVIVC: A predictive mathematical

More information

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug? Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental

More information

In Vitro-In Vivo Correlation:

In Vitro-In Vivo Correlation: In Vitro-In Vivo Correlation: Linking Drug Release to Clinical Performance Yihong Qiu, Ph.D. Abbott Laboratories 51st Land O' Lakes Conference: Bridging Material and Product Quality in Developing Tablet

More information

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997 Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products

More information

In vitro - In vivo Correlation: From Theory to Applications

In vitro - In vivo Correlation: From Theory to Applications In vitro - In vivo Correlation: From Theory to Applications Jaber Emami Department of Pharmaceutics, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran,

More information

Guideline on quality of oral modified release products

Guideline on quality of oral modified release products 20 March 2014 EMA/CHMP/QWP/428693/2013 Committee for Medicinal Products for Human Use (CHMP) Final Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public

More information

Guideline on quality of oral modified release products

Guideline on quality of oral modified release products 1 2 3 23 August 2012 EMA/492713/2012 Quality Working Party (QWP) 4 5 Draft Draft Agreed by QWP May 2012 Adoption by CHMP for release for consultation 19 July 2012 Start of public consultion 15 September

More information

Fig. 4. A two-compartment pharmacokinetic model.

Fig. 4. A two-compartment pharmacokinetic model. 3.4 Pharmacokinetic (PK) modeling and simulations Noora Sjöstedt, Wilma Kiander, Heidi Kidron 3.4.1 Introduction (Hanna Kortejärvi) Pharmacokinetic modeling and simulations can be performed with different

More information

Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation 13 December 2018 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation Draft agreed

More information

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2 Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has

More information

Comparison of the pharmacokinetics of chloroquine after single

Comparison of the pharmacokinetics of chloroquine after single Br. J. clin. Pharmac. (1986), 22, 559-564 Comparison of the pharmacokinetics of chloroquine after single intravenous and intramuscular administration in healthy Africans A. FADEKE ADEROUNMU', L. A. SALAKO',

More information

VICH GL52 on Bioequivalence: blood level bioequivalence study

VICH GL52 on Bioequivalence: blood level bioequivalence study 1 2 3 12 December 2013 EMA/CVMP/VICH/751935/2013 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 VICH GL52 on Bioequivalence: blood level bioequivalence study Draft Draft agreed by VICH

More information

Assessment of BE. Assessment of bioequivalence of implants: Appropriate study design, metrics, and acceptance criteria

Assessment of BE. Assessment of bioequivalence of implants: Appropriate study design, metrics, and acceptance criteria Assessment of BE of implants Appropriate study design, metrics, and acceptance criteria Helmut Schütz BEBAC Wikimedia Commons 2004 Arnaud Gaillard Creative Commons Attribution-ShareAlike 1.0 Generic 1

More information

NORTH CAROLINA STATE UNIVERSITY Raleigh, North Carolina

NORTH CAROLINA STATE UNIVERSITY Raleigh, North Carolina ~' ( Pharmacokinetics: A Look at Different Approaches Linda Lunney Biomath';matics Graduate Program Institute of Statistics Mimeo Series #2242 NORTH CAROLINA STATE UNIVERSITY Raleigh, North Carolina ;'

More information

Application of Direct Search Optimization for Pharmacokinetic Parameter Estimation

Application of Direct Search Optimization for Pharmacokinetic Parameter Estimation Application of Direct Search Optimization for Pharmacokinetic Parameter Estimation Received manuscript October 5th 999, Revised November 9th, 999; Accepted November 30th, 999. Farhad Khorasheh, Amir Mahbod

More information

Session 7 Clinical Trial Assessment Bioequivalence Studies

Session 7 Clinical Trial Assessment Bioequivalence Studies L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office

More information

Unit V APPLICATIONS OF PHARMACOKINETICS

Unit V APPLICATIONS OF PHARMACOKINETICS Unit V APPLICATIONS OF PHARMACOKINETICS Presented by Mrs M. Sabareesh M.Pharm., Associate Professor Department of Pharmaceutics Krishna Teja Pharmacy college Subject; ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS(17SO3202)

More information

PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS

PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS Acta Poloniae Pharmaceutica ñ Drug Research, Vol. 73 No. 3 pp. 755ñ759, 2016 ISSN 0001-6837 Polish Pharmaceutical Society PREDICTIVE PHARMACOKINETICS OF TRAMADOL HYDROCHLORIDE FLOATING TABLETS JIANMING

More information

Role of PBPK based virtual trials modeling in generic product development and regulation

Role of PBPK based virtual trials modeling in generic product development and regulation Role of PBPK based virtual trials modeling in generic product development and regulation Robert Lionberger, Ph.D. Director Office of Research and Standards Office of Generic Drugs Center for Drug Evaluation

More information

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation

More information

ORAL BIOAVAILABILITY ASSESSMENT

ORAL BIOAVAILABILITY ASSESSMENT ORAL BIOAVAILABILITY ASSESSMENT WILEY SERIES ON PHARMACEUTICAL SCIENCE AND BIOTECHNOLOGY: PRACTICES, APPLICATIONS, AND METHODS Series Editor: Mike S. Lee Milestone Development Services Mike S. Lee Integrated

More information

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation

Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation 1 2 3 21 July 2016 EMA/CHMP/458101/2016 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the qualification and reporting of physiologically based pharmacokinetic (PBPK) modelling

More information

Nature Biotechnology: doi: /nbt.1691

Nature Biotechnology: doi: /nbt.1691 a b Supplementary Figure 1. Effect of tocilizumab (TCZ) on hil-6r transgenic mice hil-6 induced SAA model. (a), (b) In vivo study of tocilizumab (TCZ) in hil-6r transgenic mice. TCZ were intravenously

More information

MEDICINES CONTROL COUNCIL

MEDICINES CONTROL COUNCIL MEDICINES CONTROL COUNCIL BIOAVAILABILTY AND BIOEQUIVALENCE OF VETERINARY MEDICINES This guideline has been prepared to serve as a recommendation to applicants wishing to submit data as evidence of efficacy

More information

INTRODUCTION TO PHARMACOLOGY

INTRODUCTION TO PHARMACOLOGY INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of

More information

Σχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) To demonstrate that two (or more) medicinal products are bioequivalent

Σχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) To demonstrate that two (or more) medicinal products are bioequivalent Σχεδιασμός κλινικών μελετών βιοϊσοδυναμίας (DESIGN OF BIOEQUIVALENCE STUDIES) AIM OF BIOEQUIVALENCE STUDIES To demonstrate that two (or more) medicinal products are bioequivalent AND Two medicinal products

More information

Line extension of immediate release products

Line extension of immediate release products EMA/EGA Joint Workshop on the Impact of the Revised EMA Guideline on Modified Release Dosage Forms Line extension of immediate release products London, 30 th April 2014 Dr. Alfredo García Arieta Jefe de

More information

Clinically Relevant Specifications (CRS): A Regulatory Perspective

Clinically Relevant Specifications (CRS): A Regulatory Perspective Clinically Relevant Specifications (CRS): A Regulatory Perspective Richard (Rik) Lostritto, Ph.D. Acting Deputy Director for Science & Policy and Acting Biopharmaceutics Lead, Office of New Drug Quality

More information

Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action

Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action 10 August 2017 EMA/CHMP/CVMP/QWP/336031/2017 Committee for Medicinal Products for Human use (CHMP) Committee for Medicinal Products for Veterinary use (CVMP) Quality Working Party (QWP) Reflection paper

More information

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00.

Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS. Lecture : 05. Practical : 04. Course Credit. Tutorial : 00. Course Title PHARMACEUTICAL FORMULATION, DEVELOPMENT & BIOPHARMACEUTICS Course Code CT113 Lecture : 05 Course Credit Practical : 04 Tutorial : 00 Total : 09 Course Objectives Upon completion of course

More information

KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training.

KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training. KEY WORDS Pharmacokinetics, modeler, hands-on, safety, practical class, clinical training. ABSTRACT After swallowing or injecting a drug, the magnitude and duration of drug effects, therapeutic and unwanted,

More information

Pharmacokinetic investigation of the absorption of oxprenolol

Pharmacokinetic investigation of the absorption of oxprenolol Br. J. clin. Pharmac. (1985), 19, 163S-169S Pharmacokinetic investigation of the absorption of oxprenolol from Oros delivery systems in healthy volunteers: comparison of in vivo and in vitro drug release

More information

Science and Quality Assurance, Part 2: PK/QA

Science and Quality Assurance, Part 2: PK/QA Science and Quality Assurance, Part 2: PK/QA Anthony B. Jones* Quality Assurance, SFBC Taylor, Princeton, NJ 08540, USA Summary For Quality Assurance to be a proactive partner in drug development we need

More information

Development of biopharmacy

Development of biopharmacy 31/10/2017 1 Development of biopharmacy Expression biopharmaceutics was composed By Gerhard Levy and it was written down by John G. Wagner in a publication from 1961 for the first time. Gerhard Levy Knowledge

More information

Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials

Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials Administrative Notice October 27, 2014 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Basic

More information

Toxicokinetic models and their applications

Toxicokinetic models and their applications Toxicokinetic models and their applications L. Zivkovic Toxicological Centre, Podgorica, Montenegro, lukazi@hdcg.co.me Abstract. In this paper toxicokinetics was examined. Chemical distribution, absorption

More information

Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products

Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products 1 2 3 21 April 2017 EMA/CVMP/EWP/016/00-Rev.3 Committee for Medicinal Products for Veterinary Use (CVMP) 4 5 6 Revised guideline on the conduct of bioequivalence studies for veterinary medicinal products

More information

In vitro in vivo correlations (IVIVC) can be summarized

In vitro in vivo correlations (IVIVC) can be summarized dx.doi.org/10.14227/dt220215p44 Use of IVIVC to Optimize Generic Development J.-M. Cardot *, G. Garrait, and E. Beyssac e-mail: j-michel.cardot@udamail.fr Auvergne University, UFR Pharmacie, EA4678, Biopharmaceutical

More information

Compartmental Pharmacokinetic Analysis. Dr Julie Simpson

Compartmental Pharmacokinetic Analysis. Dr Julie Simpson Compartmental Pharmacokinetic Analysis Dr Julie Simpson Email: julieas@unimelb.edu.au BACKGROUND Describes how the drug concentration changes over time using physiological parameters. Gut compartment Absorption,

More information

INTRODUCTION TO CLINICAL PHARMACY

INTRODUCTION TO CLINICAL PHARMACY CHAPTER 1 INTRODUCTION TO CLINICAL PHARMACY Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease

More information

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase An Executive Summary From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase Leveraging knowledge about an API s physicochemical properties

More information

Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis

Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis Simultaneous in vivo Quantification and Metabolite Identification of Plasma Samples Using High Resolution QTof and Routine MS E Data Analysis Mark Wrona, 1 Paul Rainville, 1 Eric Langlois, 2 Nigel Ewing,

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Bioavailability and Bioequivalence Studies for Orally Administered Drug Products General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes

More information

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis

More information

Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances

Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health

More information

VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS

VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS Dr Mikael Bjerg Caspersen Industrial Biotechnology Conference August 10 th 2015 INNOVATIVE TECHNOLOGY

More information

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS

QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October

More information

Pharmacokinetics as applied to in vitro and animal models

Pharmacokinetics as applied to in vitro and animal models Pharmacokinetics as applied to in vitro and animal models Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics In vitro pharmacodynamic models

More information

High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD)

High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD) High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD) Devang Shah Senior Principal Investigator Metabolism and Pharmacokinetics, Pharmaceutical

More information

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models Student Objectives for this Chapter To understand the different types of concentration - effect relationships

More information

Pharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs)

Pharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs) Pharmacokinetic / pharmacodynamic modeling and simulation in the design and analysis of Randomized Concentration-Controlled Trials (RCCTs) N. Seth Berry, PharmD Senior Scientific Advisor Quantitative Decision

More information

Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats

Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats Pharmacokinetic and pharmacodynamic evaluation of a new vascular calcification inhibitor (INS-3001) in rats M. Maillard 1, D. Mordasini,D 1. Spaggiari 2, O. Phan 1, M. Ivarsson 3, R. Maj 3, L.A. Décosterd

More information

Modern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota

Modern Pharmaceutics. Second Edition, Revised and Expanded. edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota Modern Pharmaceutics Second Edition, Revised and Expanded edited by GILBERT S. BANKER University of Minnesota Minneapolis, Minnesota CHRISTOPHER T. RHODES : ' University of Rhode Island Kingston, Rhode

More information

PHARMACOKINETICS OF DROPERIDOL IN SURGICAL PATIENTS UNDER DIFFERENT CONDITIONS OF ANAESTHESIA

PHARMACOKINETICS OF DROPERIDOL IN SURGICAL PATIENTS UNDER DIFFERENT CONDITIONS OF ANAESTHESIA Br. J. Anaesth. (),, -0 PHARACOKINETICS O DROPERIDOL IN SURGICAL PATIENTS UNDER DIERENT CONDITIONS O ANAESTHESIA K. A. LEHANN, A. VAN PEER,. IKONOAKIS, R. GASPARINI AND J. HEYKANTS Droperidol is a butyrophenone

More information

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator

Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator S830 Preclinical pharmacokinetics and pharmacodynamics of AG-519, an allosteric pyruvate kinase activator Yue Chen, Raj Nagaraja, Kha Le, Penelope A Kosinski, Gavin Histen, Charles Kung, Hyeryun Kim, Chandra

More information

Translational Pharmaceutics : a unique platform to accelerate early oncology development

Translational Pharmaceutics : a unique platform to accelerate early oncology development Translational Pharmaceutics : a unique platform to accelerate early oncology development Lisa Clarke-Lens, Associate Director, Oncology Services Quotient Clinical Clinical Operations in Oncology Trials

More information

Clinical Pharmacokinetics The Mcq Approach Telford Press

Clinical Pharmacokinetics The Mcq Approach Telford Press Clinical Pharmacokinetics The Mcq Approach Telford Press We have made it easy for you to find a PDF Ebooks without any digging. And by having access to our ebooks online or by storing it on your computer,

More information

ICH Reflection Paper Further Opportunities for Harmonization of Standards for Generic Drugs 1

ICH Reflection Paper Further Opportunities for Harmonization of Standards for Generic Drugs 1 Further Opportunities for Harmonization of Standards for Generic Drugs 1 Executive Summary This reflection paper outlines a strategic approach for developing and enhancing ICH guidelines to support the

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) GUIDELINE ON THE CONDUCT OF BIOEQUIVALENCE STUDIES FOR VETERINARY MEDICINAL PRODUCTS European Medicines Agency Veterinary Medicines and Inspections 1 2 3 London, 16 March 2009 Doc. Ref.: EMEA/CVMP/016/00-Rev.1-CONSULTATION 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) 5

More information

Clinical Pharmacology

Clinical Pharmacology Clinical Pharmacology Gene Williams, Ph.D. Team Leader, Division of Clinical Pharmacology V Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation and Research

More information

Approval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D.

Approval Review of Generic Drugs. Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Approval Review of Generic Drugs Office of Generic/OTC Drugs, PMDA Kazuyuki SAITO, Ph.D. Outline of Presentation Introduction Approval Review of Generic Drugs Equivalency review Conformity audit Conclusion

More information

PHARMACOKINETICS OF COLISTIN IN CHICKENS AT DIFFERENT AGES

PHARMACOKINETICS OF COLISTIN IN CHICKENS AT DIFFERENT AGES Bulgarian Journal of Veterinary Medicine (2003), 6, No 4, 245250 SHORT COMMUNICATION PHARMACOKINETICS OF COLISTIN IN CHICKENS AT DIFFERENT AGES A. HARITOVA, L. LASHEV & I. KANELOV Department of Pharmacology,

More information

Public Assessment Report Scientific discussion. Etoricoxib Orion (etoricoxib) SE/H/1554/01-04/DC

Public Assessment Report Scientific discussion. Etoricoxib Orion (etoricoxib) SE/H/1554/01-04/DC Public Assessment Report Scientific discussion Etoricoxib Orion (etoricoxib) SE/H/1554/01-04/DC This module reflects the scientific discussion for the approval of Etoricoxib Orion. The procedure was finalised

More information

CRED: Understanding Clinical Development Programme June 2018 Day one Chairperson: Steve Pinder, Envestia Ltd

CRED: Understanding Clinical Development Programme June 2018 Day one Chairperson: Steve Pinder, Envestia Ltd CRED: Understanding Clinical Development Programme 27-28 June 2018 Day one Chairperson: Steve Pinder, Envestia Ltd Time Activity Speaker 09.20 Registration and Coffee 09.30 Introduction to TOPRA 09.35

More information

Maximizing the Value and Utility of ADaM for Pharmacokinetic Analyses and Reporting: Much More than just ADPC and ADPP

Maximizing the Value and Utility of ADaM for Pharmacokinetic Analyses and Reporting: Much More than just ADPC and ADPP Maximizing the Value and Utility of ADaM for Pharmacokinetic Analyses and Reporting: Much More than just ADPC and ADPP James R. Johnson, PhD Sr. Principal Biostatistician/Pharmacokineticist 1 Some Basic

More information

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA

Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA Biowaiver Approaches for Solid Oral Dosage Forms in New Drug Applications Poonam R. Delvadia, Ph.D. Division of Biopharmaceutics\ONDP\OPQ\CDER\FDA PQRI BTC Webinar December 06, 2018 DISCLAIMER The presentation

More information

The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass

The research work highlights the development and evaluation of. bioavailability of drugs. The buccal route can bypass the first-pass 212 9. Summary, conclusion and recommendation 9.1 Summary and conclusion The research work highlights the development and evaluation of novel transbuccal drug antagonist of Famotidine. route have a rapid

More information

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice

The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability. WHO Biowaiver Guideline in Regulatory Practice The 13th ICDRA (16-19 September) Regulatory Approaches to proving Interchangeability WHO Biowaiver Guideline in Regulatory Practice Dr Kamel IDDIR General Director Medicines and Pharmacy Directorate Berne

More information

In vivo predictive biopharmaceutics tools for oral drug delivery

In vivo predictive biopharmaceutics tools for oral drug delivery In vivo predictive biopharmaceutics tools for oral drug delivery Bertil Abrahamsson, AstraZeneca and Mark McAllister, Pfizer Background non-absorbable drug complex complex formation drug in solid dosage

More information